Drug Profile


Alternative Names: GF-015535-00

Latest Information Update: 23 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ferrer
  • Developer Ergomed; Ferrer
  • Class 2 ring heterocyclic compounds; Acetamides; Anxiolytics; Hypnosedatives; Small molecules; Thiophenes
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Insomnia

Most Recent Events

  • 23 Aug 2016 Ferrer completes a phase II trial in Insomnia in Croatia and Poland (PO) (EudraCT2014-001966-87)
  • 04 Feb 2014 Ferrer & Ergomed Clinical Research agree to collaborate on the phase IIa trial of lorediplon for Insomnia
  • 04 Feb 2014 Lorediplon licensed to Ildong Pharmaceuticals in South Korea, Japan & China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top